Figure S1. Diagnostic odds ratio (DOR) of CAP for steatosis in suspected NAFLD patients. Figure S2. Fagan nomogram analysis of the post-test probability of CAP in the detection of ≥ S1 hepatic steatosis (Stage 0 vs Stage 1-3) in suspected NAFLD patients. Figure S3. Fagan nomogram analysis of the post-test probability of CAP in the detection of ≥ S2 hepatic steatosis (Stage 0-1 vs Stage 2-3) in suspected NAFLD patients. Figure S4. Fagan nomogram analysis of the post-test probability of CAP in the detection of ≥ S3 hepatic steatosis (Stage 0-2 vs Stage 3) in suspected NAFLD patients. Figure S5. Subgroup analysis of the diagnostic accuracy of CAP in the detection of ≥ S2 steatosis (Stage 0-1 vs Stage 2-3) in suspected NAFLD patients. Figure S6...
Controlled attenuation parameter (CAP) is a noninvasive, quantitative, fast, and reliable novel tool...
Table S1. Relative Risk of some factors in normal and NAFLD groups. Table S2. Variable scoring list ...
Background & Aims: Controlled attenuation parameter (CAP) can measure hepatic steatosis. However...
Abstract Background Controlled attenuation parameter (CAP) is a non-invasive method for diagnosing h...
Table S1. Characteristics of the primary-care databases included in the study. Figure S1. Identifica...
Electronic Supplementary Material: Figure S1. Histogram of MRI-derived liver fat content (%) values....
Odds ratios for NAFLD in different quartiles of TyG index or ALT in ALT <40 and âĽ40 U/L groups. Ta...
August 31, 2014. Quality Assessment of Diagnostic Accuracy Studies checklist was used to assess the ...
Background & Aims The prevalence of fatty liver underscores the need for non-invasive characterizati...
BACKGROUND: Diagnostic tools for liver disease can now include estimation of the grade of hepatic st...
(upper panel) Relationship between liver stiffness and CAP values in patients with risk factors for ...
Table S1. Stratified analysis of NAFLD and platelet count in different subgroup. (DOCX 27 kb
Table S1. Prevalence of comorbidities in overweight (Nâ=â14) and obese (12) NAFLD patients. In o...
Volcano plot [−log10 (p-value) vs. log2 (fold-change)] for the comparison between the baseline and f...
BACKGROUND:Primary care is the ideal setting for early identification of patients with non-alcoholic...
Controlled attenuation parameter (CAP) is a noninvasive, quantitative, fast, and reliable novel tool...
Table S1. Relative Risk of some factors in normal and NAFLD groups. Table S2. Variable scoring list ...
Background & Aims: Controlled attenuation parameter (CAP) can measure hepatic steatosis. However...
Abstract Background Controlled attenuation parameter (CAP) is a non-invasive method for diagnosing h...
Table S1. Characteristics of the primary-care databases included in the study. Figure S1. Identifica...
Electronic Supplementary Material: Figure S1. Histogram of MRI-derived liver fat content (%) values....
Odds ratios for NAFLD in different quartiles of TyG index or ALT in ALT <40 and âĽ40 U/L groups. Ta...
August 31, 2014. Quality Assessment of Diagnostic Accuracy Studies checklist was used to assess the ...
Background & Aims The prevalence of fatty liver underscores the need for non-invasive characterizati...
BACKGROUND: Diagnostic tools for liver disease can now include estimation of the grade of hepatic st...
(upper panel) Relationship between liver stiffness and CAP values in patients with risk factors for ...
Table S1. Stratified analysis of NAFLD and platelet count in different subgroup. (DOCX 27 kb
Table S1. Prevalence of comorbidities in overweight (Nâ=â14) and obese (12) NAFLD patients. In o...
Volcano plot [−log10 (p-value) vs. log2 (fold-change)] for the comparison between the baseline and f...
BACKGROUND:Primary care is the ideal setting for early identification of patients with non-alcoholic...
Controlled attenuation parameter (CAP) is a noninvasive, quantitative, fast, and reliable novel tool...
Table S1. Relative Risk of some factors in normal and NAFLD groups. Table S2. Variable scoring list ...
Background & Aims: Controlled attenuation parameter (CAP) can measure hepatic steatosis. However...